Skip to content

Autophagy enhancement via Curcumin-Rapamycin microdosing combination

MedicOath Autonomous Discovery Engine

Zenodo (CERN European Organization for Nuclear Research) April 28, 2026 DOI: 10.5281/zenodo.19833227 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical study Peer reviewed
Population AGS cells
Interventions Rapamycin Bioavailable curcumin formulation
Dose 0.1 mg weekly (rapamycin)
Topics Microdosing
Keywords Autophagy Tfeb Curcumin Organelle Nucleic acid Bioavailability Lysosome Cell biology Pharmacology Biochemistry Cancer research
Key points Ultra-low dose rapamycin combined with bioavailable curcumin enhances TFEB nuclear translocation and autophagy to clear nucleic acids and damaged organelles, reducing interferon responses in AGS cells.

Abstract

Ultra-low dose rapamycin (0.1mg weekly) combined with bioavailable curcumin formulation enhances TFEB nuclear translocation and ULK1-Beclin1-ATG5 autophagy machinery to clear accumulated nucleic acids and damaged organelles triggering interferon responses in AGS.

Comparable studies

Other preclinical and animal studies on microdosing, most cited first.

Explore topics